Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$0.72 -0.02 (-2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+1.10%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYX vs. GNLX, FTLF, TARA, KRRO, SKYE, ACTU, ALTS, ATOS, CLLS, and BHST

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Genelux (GNLX), FitLife Brands (FTLF), Protara Therapeutics (TARA), Korro Bio (KRRO), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), ALT5 Sigma (ALTS), Atossa Genetics (ATOS), Cellectis (CLLS), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs. Its Competitors

SCYNEXIS (NASDAQ:SCYX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

SCYNEXIS has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Genelux has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500.

Genelux has a consensus price target of $17.75, suggesting a potential upside of 433.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than SCYNEXIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Genelux
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

SCYNEXIS has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$3.75M7.54-$21.29M-$0.56-1.29
Genelux$10K12,574.08-$29.87M-$0.88-3.78

Genelux has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-1,030.04% -53.47% -32.86%
Genelux N/A -93.04%-74.17%

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by insiders. Comparatively, 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Genelux had 3 more articles in the media than SCYNEXIS. MarketBeat recorded 3 mentions for Genelux and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.87 beat Genelux's score of 0.91 indicating that SCYNEXIS is being referred to more favorably in the media.

Company Overall Sentiment
SCYNEXIS Very Positive
Genelux Positive

Summary

SCYNEXIS and Genelux tied by winning 8 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISMED IndustryMedical SectorNASDAQ Exchange
Market Cap$28.88M$2.73B$5.52B$9.41B
Dividend YieldN/A1.79%3.80%4.04%
P/E RatioN/A8.9428.0419.84
Price / Sales7.54697.47429.5399.59
Price / CashN/A161.2635.8457.94
Price / Book0.505.008.125.65
Net Income-$21.29M$30.99M$3.25B$258.00M
7 Day Performance3.13%1.69%0.97%2.09%
1 Month Performance-2.62%9.20%7.36%11.13%
1 Year Performance-65.31%-1.25%31.31%18.40%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.9185 of 5 stars
$0.73
-2.0%
N/A-65.9%$28.88M$3.75M-1.2960Positive News
GNLX
Genelux
1.2612 of 5 stars
$3.38
-1.5%
$17.75
+425.1%
+38.8%$127.54MN/A-3.8410News Coverage
FTLF
FitLife Brands
3.9678 of 5 stars
$13.09
+0.5%
$20.50
+56.6%
-16.1%$122.92M$64.47M15.5820
TARA
Protara Therapeutics
2.0848 of 5 stars
$3.16
+3.6%
$20.50
+548.7%
+36.5%$121.91MN/A-1.8430
KRRO
Korro Bio
1.8225 of 5 stars
$12.97
+2.0%
$102.43
+689.7%
-71.4%$121.79M$2.27M-1.3770
SKYE
Skye Bioscience
2.2344 of 5 stars
$3.93
-1.3%
$16.60
+322.4%
-41.0%$121.73MN/A-4.7911
ACTU
Actuate Therapeutics
2.7981 of 5 stars
$6.20
+1.0%
$20.50
+230.6%
N/A$121.64MN/A0.0010News Coverage
Positive News
ALTS
ALT5 Sigma
0.086 of 5 stars
$6.96
-11.7%
N/AN/A$121.45M$12.53M0.00170
ATOS
Atossa Genetics
3.1832 of 5 stars
$0.94
-0.2%
$6.17
+558.4%
-37.4%$120.98MN/A-4.468Positive News
CLLS
Cellectis
3.4283 of 5 stars
$2.15
+35.2%
$4.00
+86.0%
-8.5%$119.50M$49.22M-2.50290High Trading Volume
BHST
BioHarvest Sciences
N/A$7.05
-1.8%
$13.67
+93.9%
N/A$115.80M$27.70M-14.10N/A

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners